GTX (NASDAQ: GTXI) and Charles River Laboratories Intl. (NYSE:CRL) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.
This is a summary of current ratings and recommmendations for GTX and Charles River Laboratories Intl., as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Charles River Laboratories Intl.||0||5||5||0||2.50|
Earnings & Valuation
This table compares GTX and Charles River Laboratories Intl.’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Charles River Laboratories Intl.||$1.68 billion||3.04||$154.76 million||$4.09||26.38|
Charles River Laboratories Intl. has higher revenue and earnings than GTX. GTX is trading at a lower price-to-earnings ratio than Charles River Laboratories Intl., indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
GTX has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Charles River Laboratories Intl. has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
Insider & Institutional Ownership
11.6% of GTX shares are owned by institutional investors. Comparatively, 95.9% of Charles River Laboratories Intl. shares are owned by institutional investors. 41.2% of GTX shares are owned by insiders. Comparatively, 2.2% of Charles River Laboratories Intl. shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares GTX and Charles River Laboratories Intl.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Charles River Laboratories Intl.||10.72%||26.58%||8.92%|
Charles River Laboratories Intl. beats GTX on 9 of the 13 factors compared between the two stocks.
GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.
About Charles River Laboratories Intl.
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company’s clients’ manufacturing activities.
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.